Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin
about
Solution structure of midkine, a new heparin-binding growth factorIdentification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophinMidkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell typesPleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growthNeointima formation in a restenosis model is suppressed in midkine-deficient miceThe pro-angiogenic cytokine pleiotrophin potentiates cardiomyocyte apoptosis through inhibition of endogenous AKT/PKB activityPleiotrophin induces angiogenesis: involvement of the phosphoinositide-3 kinase but not the nitric oxide synthase pathways.Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/ConneEffect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.Pleiotrophin (PTN) is expressed in vascularized human atherosclerotic plaques: IFN-{gamma}/JAK/STAT1 signaling is critical for the expression of PTN in macrophages.Structure and phylogenetic analysis of an endogenous retrovirus inserted into the human growth factor gene pleiotrophin.Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.The synthetic peptide P111-136 derived from the C-terminal domain of heparin affin regulatory peptide inhibits tumour growth of prostate cancer PC-3 cells.Pleiotrophin regulates serine phosphorylation and the cellular distribution of beta-adducin through activation of protein kinase CCurrent status of ribozymes as gene therapy agents for cancer.Translocations involving anaplastic lymphoma kinase (ALK).A secreted FGF-binding protein can serve as the angiogenic switch in human cancer.Pleiotrophin (PTN) expression and function and in the mouse mammary gland and mammary epithelial cells.Expression of pleiotrophin in the prostate is androgen regulated and it functions as an autocrine regulator of mesenchyme and cancer associated fibroblasts and as a paracrine regulator of epithelia.PTN signaling: Components and mechanistic insights in human ovarian cancer.Dominant negative pleiotrophin induces tetraploidy and aneuploidy in U87MG human glioblastoma cells.Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastrointestinal carcinomas.Therapeutic silence of pleiotrophin by targeted delivery of siRNA and its effect on the inhibition of tumor growth and metastasis.ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers.SPAG9 controls the cell motility, invasion and angiogenesis of human osteosarcoma cells.Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo.Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK.Menin represses malignant phenotypes of melanoma through regulating multiple pathways.Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin.Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas.The role of the metastasis suppressor gene KAI1 in melanoma angiogenesis.Integrin-linked kinase regulates melanoma angiogenesis by activating NF-κB/interleukin-6 signaling pathway.Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesisRecruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase.The future of dermatopathology.Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas.Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma.Message therapy: gene therapy that targets mRNA sequence and stability.New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.
P2860
Q24310244-9D734F6A-FCE8-4332-88F0-F7498A5624A1Q28208159-E4E5FE79-10B1-44DF-B66D-F33C7755D020Q28214927-08E6C93A-1314-4F26-8BD1-6B0944AC1C8FQ28216536-D44D6CC2-5B63-45BE-8014-C3E2C2E7D854Q28573235-388B8ECA-6188-4D31-A1D8-86EDFDF596D6Q28581466-C86D3821-77C6-42B6-BD43-997D5F1C76A9Q32160506-FD2DD873-DA58-4826-BFBB-681A112B9FF1Q33301092-E65893C0-2067-4A18-B687-85A874903D73Q33487136-38D7FD2B-50C1-4845-8B94-728410E0716FQ33694574-50519C80-E4E9-4DB6-B784-5DAB4B303E13Q33785721-0F16A51B-8F03-4F28-A42B-53ECC8AA388BQ33822119-BCE08EFC-7D15-44F8-B12E-CBE12A899ADDQ33915644-AC599AE5-2BC0-4582-94D2-F0DA92AD5539Q33934009-9581A309-B70C-4BE4-B286-7F8C79DB5026Q34311089-5E41D312-7A43-4EFF-A85F-452AA1FF47A8Q34405439-4E56F931-8D28-4488-A702-21153F7AD34DQ34442731-50A794A4-A2C2-4D27-9998-7D0F37853561Q34451087-88A285E8-DDB0-4EDB-B81D-30DE51F8448FQ34609566-B44D966B-17E6-46C4-A633-D28E8BECECF6Q35685365-29469D3C-5A9F-427B-924D-F1A13907D345Q35748364-371E3B59-63B5-4368-8F65-6266B1396065Q36115346-D5666AE9-F148-4642-A21B-EC2E9B8296B3Q36386418-68E82627-9F08-4FA7-9AA3-8EB5BD3D45F0Q36477122-5B4D1BFB-5A2A-4C51-AE58-2735470D2DEEQ36524476-5A965EB1-7FD7-4FB4-AF38-7A007BCF6560Q36631534-28396C10-60E5-4B46-82CA-1851EF3603F6Q37073265-BCCA8D3A-7536-4450-B0C1-08D72374515BQ37294848-3E729689-2F0F-4D49-AFD7-42CDAC072E1CQ37411178-371CC308-A1F9-42DD-9DDD-589364D25443Q38315381-BE311396-B43A-498F-A49C-FD204BBC492FQ38813736-423D71A4-87CB-4BF2-B7CF-C448B3701E10Q38850581-B3E172D0-C6CF-4565-8514-1981D353A295Q39600634-632DBFC8-2679-40E7-8EEC-23A31247E5D3Q39721556-4AFCAF73-D76E-42A9-93D0-A3ABBABDBEB5Q40249798-F25EA391-EFDE-4DD8-A4F6-20A4B886676CQ40371990-408AE5E9-41BE-4836-8451-5C968081D0B0Q40604566-11AD5761-9143-4E66-BD2F-37BDE456EF91Q40783176-185A1E16-2A4B-427D-ABBD-904C54DFF738Q41650542-966E53DA-65CB-48BB-B173-68B4187523EBQ42153007-178A15C2-A811-436C-8A94-D7F3348A7EA7
P2860
Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Melanoma angiogenesis and meta ...... ted growth factor pleiotrophin
@en
Melanoma angiogenesis and meta ...... ed growth factor pleiotrophin.
@nl
type
label
Melanoma angiogenesis and meta ...... ted growth factor pleiotrophin
@en
Melanoma angiogenesis and meta ...... ed growth factor pleiotrophin.
@nl
prefLabel
Melanoma angiogenesis and meta ...... ted growth factor pleiotrophin
@en
Melanoma angiogenesis and meta ...... ed growth factor pleiotrophin.
@nl
P2093
P2860
P356
P1476
Melanoma angiogenesis and meta ...... ted growth factor pleiotrophin
@en
P2093
A M Schulte
A Wellstein
F Czubayko
G J Berchem
P2860
P304
14753-14758
P356
10.1073/PNAS.93.25.14753
P407
P577
1996-12-01T00:00:00Z